Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

Swapna ThotaBhumika J PatelMeena SadapsSuresh BalasubramanianSrinivasa SanikommuCassandra HirschSerena MarottaMikkael A SekeresAntonio Maria RisitanoJaroslaw P Maciejewski

Published in: British journal of haematology (2017)

Keyphrases

low dose
bone marrow
mesenchymal stem cells
high dose
type diabetes
skeletal muscle
glycemic control
insulin resistance